Skip to main content

Table 2 Overall responses

From: Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion

 

T790M negative (n = 33)

T790M positive (n = 30)

 

With PE (n = 12)

Without PE (n = 21)

p-Value

With PE (n = 12)

Without PE (n = 18)

p-Value

CR

0

(0.0%)

0

(0.0%)

 

0

(0.0%)

0

(0.0%)

 

PR

7

(58.3%)

15

(71.4%)

 

8

(66.7%)

15

(83.3%)

 

SD

4

(33.3%)

5

(23.8%)

 

4

(33.3%)

3

(16.7%)

 

PD

1

(8.3%)

0

(0.0%)

 

0

(0.0%)

0

(0.0%)

 

NE

0

(0.0%)

1

(4.8%)

 

0

(0.0%)

0

(0.0%)

 

ORR

 

58.3%

 

71.4%

0.443

 

66.7%

 

83.3%

0.290

DCR

 

91.7%

 

95.2%

0.679

 

100.0%

 

100.0%

NA

  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluated, ORR objective response rate, DCR disease control rate, NA not applicable